Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery

International Journal of Pharmaceutics

Volumn 365, Issue 1-2, 2009, Pages 162-169

  Pilcer, Gabrielle ^a   Vanderbist, Francis ^b   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Laboratoires SMB SA   (Belgium)

Author keywords

Dry powder inhalation (DPI); Nanoparticles; Pulmonary delivery; Spray drying; Tobramycin

Indexed keywords

GLYCOCHOLATE SODIUM; NANOPARTICLE; TOBRAMYCIN;

ARTICLE; DRUG FORMULATION; DRY POWDER; LASER DIFFRACTION; PARTICLE SIZE; PRIORITY JOURNAL; SPRAY DRYING; SUSPENSION;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; GLYCOCHOLIC ACID; LASERS; LUNG; MICROSPHERES; NANOPARTICLES; PARTICLE SIZE; POWDERS; TECHNOLOGY, PHARMACEUTICAL; TOBRAMYCIN;

EID: 57049159889     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.08.014     Document Type: Article

References (21)

1. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., and Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulize technology and nanoparticle characteristics on aerosol features. J. Control. Release 86 (2003) 131-144
2. Finlay W.H., Stapleton K.W., and Zuberbuhler P. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulised aerosols. J. Aerosol Sci. 28 (1997) 1301-1309
3. Finlay W.H., and Gehmlich M.G. Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates. Int. J. Pharm. 210 (2000) 83-95
4. Gelperina S., Kisich K., Iseman M.D., and Heifets L. The potential advantages of nanoparticles drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 172 (2005) 1487-1497
5. Grau M.J., Kayser O., and Müller R.H. Nanosuspensions of poorly soluble drugs-reproducibility of small scale production. Int. J. Pharm. 196 (2000) 155-157
6. Grenha A., Seijo B., and Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 25 (2005) 427-437
7. Grenha A., Grainger C.I., Dailey L.A., Seijo B., Martin G.P., Remunan-Lopez C., and Forbes B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur. J. Pharm. Sci. 31 (2007) 73-84
8. Hadinoto K., Phanapavudhikul P., Zhu K., and Tan R.B.H. Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind. Eng. Chem. Res. 45 (2006) 3697-3706
9. Hadinoto K., Phanapavudhikul P., Kewu Z., and Tan R. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int. J. Pharm. 333 (2007) 187-198
10. Hadinoto K., Zhu K., and Tan R.B.H. Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Eur. J. Pharm. 341 (2007) 195-206
11. Hecq J., Deleers M., Fanara D., Vranckx H., and Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299 (2005) 167-177
12. Hickey A.J., Martonen T.B., and Yang Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharm. Acta Helv. 71 (1996) 185-190
13. Hickey A.J. Delivery of drugs by the pulmonary route. In: Banker J.S., and Rhodes C.T. (Eds). Modern Pharmaceutics. fourth edition, revised and expanded vol. 121 (2002), Marcel Dekker, New York 479-501
14. Kipp J.E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 295 (2004) 269-281
15. Krause K.P., and Müller R.H. Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int. J. Pharm. 214 (2001) 21-24
16. LaVan D.A., McGuire T., and Langer R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 21 (2003) 1184-1192
17. Pandey R., and Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chem. 55 (2005) 430-439
18. Pilcer G., Sebti Th., and Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm. Res. 23 (2006) 931-940
19. Sham J.-O.H., Zhang Y., Finlay W.H., Roa W.H., and Löbenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 269 (2004) 457-467
20. Tsapsis N., Bennett D., Jackson B., Weitz D.A., and Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12001-12005
21. Weers J.G. Dispersible powders for inhalation applications. Innov. Pharm. Technol. 1 (2000) 111-116